Aurinia Pharmaceuticals AUPH Cash Flow Statement
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| $287.2M+4,893% | $5.75M+107% | -$78.02M+27.9% | -$108.18M+40.2% | ||
| $19.45M0.0% | $19.45M+67.0% | $11.65M+330% | $2.71M+48.8% | ||
| $14.68M-53.5% | $31.6M-30.3% | $45.31M+40.3% | $32.3M+3.4% | ||
| $135.66M+206% | $44.39M— | —— | —— | ||
| —— | —— | -$6.71M— | —— | ||
| $98.16M+144% | $40.24M— | $0— | $0— | ||
| -$106.11M-116% | -$49.09M-857% | -$5.13M-311% | $2.43M-98.9% | ||
| —— | $34.56M+172% | -$47.78M— | —— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where does Aurinia Pharmaceuticals's cash flow data come from?
- Every line is extracted from Aurinia Pharmaceuticals's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.